Advertisement
YOU ARE HERE: LAT HomeCollectionsSamuel Colella
IN THE NEWS

Samuel Colella

FEATURED ARTICLES
BUSINESS
February 8, 2005 | From Associated Press
Takeda Pharmaceutical Co. said Monday that it would acquire Syrrx Inc., a privately held California biotechnology company working on treatments for cancer and diabetes. Takeda, Japan's largest drug maker, will buy San Diego-based Syrrx for about $270 million in cash, the company said. The purchase of Syrrx will enable Takeda to gain access to innovations in medical research. Takeda had made it clear it was also keen to have a research base in the U.S., the world's largest pharmaceutical market.
ARTICLES BY DATE
Advertisement
BUSINESS
March 13, 2003 | Denise Gellene, Times Staff Writer
The funding outlook for biomedical companies is miserable, venture capitalists and local biotech executives said Wednesday at a conference in Los Angeles. Samuel D. Colella, managing director of Versant Ventures of Menlo Park, Calif., said that although venture firms nationally have $70 billion in uncommitted cash, many investment firms are likely to "sit on the sidelines and wait for better times."
Los Angeles Times Articles
|